Medscape1d
GLP-1 Reduces Recurrent Ischemic Stroke in Type 2 Diabetes
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
Medscape19h
GLP-1 Therapies for HFpEF: Optimizing Outcomes Through Patient-Centered Care
Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!
Medical News Today24d
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...
Endocrinology Advisor4d
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.